Hubei Guangji Pharmaceutical Co., Ltd. (SHE:000952)
China · Delayed Price · Currency is CNY 6.81
-0.08 (-1.16%)
May 28, 2026, 3:04 PM CST
SHE:000952 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 626.91 | 612.31 | 635.05 | 730.11 | 794.85 | 785.1 |
Other Revenue | 11.67 | 11.67 | 3.75 | 7.71 | 2.79 | 0.47 |
| 638.58 | 623.97 | 638.8 | 737.82 | 797.64 | 785.57 | |
Revenue Growth (YoY) | 5.18% | -2.32% | -13.42% | -7.50% | 1.54% | 14.15% |
Cost of Revenue | 504.2 | 483.2 | 524.77 | 549.89 | 510.22 | 487.42 |
Gross Profit | 134.38 | 140.77 | 114.03 | 187.93 | 287.42 | 298.15 |
Selling, General & Admin | 217.47 | 228.16 | 263.03 | 194.83 | 149.94 | 137.29 |
Research & Development | 36.7 | 41.91 | 56.82 | 74.75 | 68.98 | 52.06 |
Other Operating Expenses | 17.62 | 16.7 | 14.03 | 12.92 | 13.5 | 15.97 |
Operating Expenses | 278.36 | 294.05 | 331.08 | 282.64 | 236.3 | 210.87 |
Operating Income | -143.98 | -153.28 | -217.04 | -94.7 | 51.13 | 87.28 |
Interest Expense | -52.86 | -51.16 | -61.98 | -49.15 | -21.1 | -16.71 |
Interest & Investment Income | 19.26 | 19.41 | 2.06 | 3.46 | 8.31 | 21.95 |
Currency Exchange Gain (Loss) | -0.16 | -0.16 | 4.31 | 2.07 | 4.33 | -2.11 |
Other Non Operating Income (Expenses) | -4.47 | -2.81 | -0.38 | -0.04 | -1.01 | 7.3 |
EBT Excluding Unusual Items | -182.21 | -188 | -273.03 | -138.36 | 41.65 | 97.72 |
Gain (Loss) on Sale of Investments | -0.36 | - | -27.92 | -10.02 | - | - |
Gain (Loss) on Sale of Assets | 0.55 | 0.55 | -2.4 | 0.25 | -4.31 | 0.54 |
Asset Writedown | -264.87 | -265.29 | -30.68 | -0.12 | -0.14 | -0.01 |
Legal Settlements | - | - | 1.04 | 0.9 | -0.75 | 5.55 |
Other Unusual Items | 9.63 | 9.64 | 12.71 | 6.69 | 23.63 | 20.54 |
Pretax Income | -437.27 | -443.1 | -320.29 | -140.67 | 60.08 | 124.34 |
Income Tax Expense | -4.69 | -4.16 | -5.16 | 11.75 | 12.4 | 18.53 |
Earnings From Continuing Operations | -432.57 | -438.95 | -315.13 | -152.41 | 47.68 | 105.81 |
Minority Interest in Earnings | 32.7 | 34.45 | 19.84 | 12.17 | 2.65 | 4.3 |
Net Income | -399.87 | -404.49 | -295.29 | -140.25 | 50.33 | 110.11 |
Net Income to Common | -399.87 | -404.49 | -295.29 | -140.25 | 50.33 | 110.11 |
Net Income Growth | - | - | - | - | -54.29% | 47.50% |
Shares Outstanding (Basic) | 348 | 348 | 352 | 354 | 351 | 344 |
Shares Outstanding (Diluted) | 348 | 348 | 352 | 354 | 353 | 344 |
Shares Change (YoY) | -0.94% | -1.01% | -0.60% | 0.36% | 2.54% | 2.85% |
EPS (Basic) | -1.15 | -1.16 | -0.84 | -0.40 | 0.14 | 0.32 |
EPS (Diluted) | -1.15 | -1.16 | -0.84 | -0.40 | 0.14 | 0.32 |
EPS Growth | - | - | - | - | -55.42% | 43.41% |
Free Cash Flow | 62.98 | 24.79 | -154.28 | -715.1 | -158.63 | -20.7 |
Free Cash Flow Per Share | 0.18 | 0.07 | -0.44 | -2.02 | -0.45 | -0.06 |
Dividend Per Share | - | - | - | - | - | 0.060 |
Gross Margin | 21.04% | 22.56% | 17.85% | 25.47% | 36.03% | 37.95% |
Operating Margin | -22.55% | -24.57% | -33.98% | -12.83% | 6.41% | 11.11% |
Profit Margin | -62.62% | -64.83% | -46.23% | -19.01% | 6.31% | 14.02% |
Free Cash Flow Margin | 9.86% | 3.97% | -24.15% | -96.92% | -19.89% | -2.63% |
EBITDA | 14.51 | 6.35 | -52.84 | 24.04 | 148.58 | 178.15 |
EBITDA Margin | 2.27% | 1.02% | -8.27% | 3.26% | 18.63% | 22.68% |
D&A For EBITDA | 158.49 | 159.63 | 164.2 | 118.75 | 97.45 | 90.87 |
EBIT | -143.98 | -153.28 | -217.04 | -94.7 | 51.13 | 87.28 |
EBIT Margin | -22.55% | -24.57% | -33.98% | -12.83% | 6.41% | 11.11% |
Effective Tax Rate | - | - | - | - | 20.64% | 14.90% |
Revenue as Reported | 638.58 | 623.97 | 638.8 | 737.82 | 797.64 | 785.57 |
Advertising Expenses | - | 2.51 | 15.88 | 9.05 | 5.84 | 6.12 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.